Arecor Therapeutics plc (AIM:AREC)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 24.92M |
| Revenue (ttm) | 1.71M |
| Net Income (ttm) | 664.00K |
| Shares Out | 37.76M |
| EPS (ttm) | 0.02 |
| PE Ratio | 27.93 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,299 |
| Average Volume | 17,072 |
| Open | 62.00 |
| Previous Close | 66.00 |
| Day's Range | 62.00 - 70.00 |
| 52-Week Range | 36.60 - 100.00 |
| Beta | -0.20 |
| RSI | 40.56 |
| Earnings Date | Apr 13, 2026 |
About Arecor Therapeutics
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes;... [Read more]
Financial Performance
Financial StatementsNews
Arecor Therapeutics Earnings Call Transcript: H2 2025
Revenue and cash position improved, supported by a $11M non-dilutive financing and reduced expenses. AT278 insulin and oral peptide delivery platforms advance, with phase II trials and key data expected in 2026. Strategic partnerships and a strong cash runway support growth.
Arecor Therapeutics Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
AT278, an ultra-concentrated, ultra-rapid insulin, targets unmet needs in AID systems, with phase II trials planned and a $3–5 billion U.S. market opportunity. The company is also advancing an oral peptide delivery platform, aiming to improve GLP-1 bioavailability and expand partnerships.
Half Year 2025 Arecor Therapeutics PLC Earnings Presentation Transcript
Half Year 2025 Arecor Therapeutics PLC Earnings Presentation Transcript
AIM Market Roundup: Wishbone, Nativo Resources, Arecor Therapeutics
Wishbone, Nativo Resources, Arecor Therapeutics, Proteome Sciences and Bradda Head Lithium are today's top movers on London's AIM market
Arecor Therapeutics Earnings Call Transcript: H1 2025
Strong progress on strategic R&D focus, highlighted by a co-development deal for AT278 with Sequel MedTech and a royalty financing agreement with Ligand, extends cash runway into H1 2027. Revenue remains steady, costs are controlled, and key clinical and platform milestones are on track.
LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor
LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor
Arecor extends cash runway with US partnerships
Arecor has bolstered its balance sheet and sharpened its clinical focus, signing two US partnerships that will accelerate its drug pipeline.
AIM Market Roundup: The Revel Collective, Tanfield, Arecor
The Revel Collective, Tanfield, Arecor are today's top risers, while Pantheon Resources, Acuity RM take the biggest fall on London's AIM
Full Year 2024 Arecor Therapeutics PLC Earnings Presentation (Shareholder Q&A) Transcript
Full Year 2024 Arecor Therapeutics PLC Earnings Presentation (Shareholder Q&A) Transcript
Arecor Therapeutics Earnings Call Transcript: H2 2024
Revenues grew 11% to $5.1M, driven by AT220 royalties and Tetris products, while R&D costs fell. AT278 and AT247 showed clinical superiority, and the oral peptide platform advanced, with strong IP and new partnerships supporting future growth.
Arecor Therapeutics Transcript: Investor Update
Operations at Tetris Pharma will cease following a strategic review, with Ogluo rights returned to Xeris due to rising costs and reduced margins. Focus shifts to proprietary insulin and oral peptide programs, with inventory sell-through expected to fund future growth.
Arecor Therapeutics Earnings Call Transcript: H1 2024
Revenue grew 20% year-over-year, driven by proprietary and partnered products, with AT278 showing superior clinical results and Ogluo expanding in key markets. A recent £6.4 million fundraise extends the cash runway to 24 months, supporting R&D and commercial growth.
Half Year 2024 Arecor Therapeutics PLC Earnings Presentation Transcript
Half Year 2024 Arecor Therapeutics PLC Earnings Presentation Transcript
Arecor Therapeutics Earnings Call Transcript: H1 2024
H1 2024 saw revenue growth from diversified streams, a strengthened balance sheet after a GBP 6.4m fundraise, and clinical advances in diabetes and obesity. AT278 showed best-in-class results, driving strong interest from partners, while Ogluo faces a short-term packaging issue.